Odense University Hospital
Odense, Fyn, 5000, Denmark
NCT Number: NCT02072798
Background Women undergoing Caesarean Section (CS) have an increased risk of postpartum infections compared to women undergoing vaginal delivery. In Denmark the incidence of post-CS infections is 7-10%. The most common infections are endometritis, Urinary tract infections (UTI) and wound infections (WI).
Prophylactic antibiotics are effective in preventing postoperative infections and national guidelines recommend that antibiotics should be administered as a single dose immediately before surgical incision. CS is an exception to this pre-incision administration approach. National guidelines recommend administration of antibiotics after umbilical cord clamping to avoid exposure of the child to antibiotics before birth. Recent studies of antibiotic prophylaxis for CS suggest that prophylactic antibiotics administered before incision compared to after umbilical cord clamping may reduce post-CS infections by up to 50%. Two Cochrane reviews from 2012 criticize these types of studies for lack of data for outcomes on the baby and on late infection in the mother.
At birth, all mammals must rapidly adapt to intake of complex milk nutrients via the gut and simultaneously tolerate the invasion of billions of microbes. This requires rapid maturation of the digestive and immune functions to avoid gut disorders and infections. Full-term, breast-fed infants normally adapt well, but factors such as caesarean birth, high hygiene levels, antibiotics treatment and formula feeding may inhibit immune development both short and long term. Birth by caesarean section in high-hygiene hospital environments, and widespread use of antibiotics, are factors that reduce gut microbiota density and diversity in the newborn for some time after birth. On the other hand, high-hygiene environments and antibiotics are essential tools to combat infections, especially for the weakest newborn infants.
This pilot study will be a feasibility study to the original study, which examines the effect of change in timing of prophylactic antibiotics on the rate of post-CS infections (endometritis, UTI and WI). The pilot study focus on antibiotic and changes in the gut microbiota of newborn infants. The feasibility study will only include pregnant women in Odense with a body mass index below 30, and planned cesarean section.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Phase 4
Odense, Fyn, 5000, Denmark
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
Other names: Cefuroxime "Fresenius Kabi"
Time frame: Within the first 30 days after surgery
Time frame: on the tenth day of life
Time frame: Within the first 30 days after Caesarean Section
Time frame: Within the first 30 days after Caesarean Section
Time frame: within the first 30 days after Caesarean Section
Time frame: during the first 24 hours of life
Time frame: On the third day of life
Odense University Hospital
Other
Antibiotic Prophylaxis for Postpartum Infections Following Caesarean Section
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01890720
Body Weight, Cesarean Section; Dehiscence
Aarhus, Jutland, Denmark
View Trial DetailsNCT01891006
Cesarean Section; Dehiscence, Complications; Cesarean Section
Odense, Denmark
View Trial DetailsNCT00603603
Adnexal Diseases, Endometritis
St Louis, Missouri, United States
View Trial DetailsNCT04256798
Anesthesia, Chlorhexidine
Botucatu, São Paulo, Brazil
View Trial Details